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 Abstract 
The small integrin-binding ligand N-linked glycoprotein (SIBLING) family consists of osteopontin 
(OPN), bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP) 
and matrix extracellular phosphoglycoprotein (MEPE). These proteins share many structural 
characteristics and are primarily located in bone and dentin. Accumulating evidence has implicated 
the SIBLING proteins in matrix mineralization. Therefore, in this review we discuss the individual 
role that each of the SIBLING proteins has in this highly orchestrated process. In particular, we will 
emphasise how the nature and extent of their proteolytic processing and post-translational 
modification affects their functional role. Finally we establish what role the SIBLING proteins have in 
clinical disorders of hypophosphatemia and their potential therapeutic use.   
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The skeleton is a highly intricate and complex organ that has a range of functions spanning from 
locomotion to ion homeostasis. It is structurally adapted to suit its function; strong and stiff to 
withstand loading, and yet light for movement and flexible to prevent fracture. The organic 
component of bone, termed the osteoid, comprises of an extracellular matrix (ECM) composed 
primarily of collagen type I together with several non-collagenous proteins (NCPs).  
One such family of NCPs is the small integrin-binding ligand N-linked glycoprotein (SIBLING) 
family. This consists of osteopontin (OPN), bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), 
dentin sialophosphoprotein (DSPP) and matrix extracellular phosphoglycoprotein (MEPE). It is likely 
that this protein family arose from the sectrotry calcium-binding phosphoprotein (SCPP) family by 
gene duplication, due to their similar structural features (Kawasaki & Weiss 2006). Despite having 
little intrinsic sequence homology, the SIBLING family of proteins share some common 
characteristics (Fisher et al. 2001). All are located to a 375kb region on the human chromosome 4q21, 
and 5q in mouse, and have similar exon structures (Huq et al. 2005). The SIBLING proteins are 
principally expressed in bone and dentin, and are secreted into the ECM during osteoid formation and 
subsequent mineralisation.  
All SIBLING proteins undergo similar post translational modifications (PTMs) such as 
phosphorylation and glycosylation, the extent of which is crucial in determining their function 
(Boskey et al. 2009). It has long been known that the SIBLING proteins have an Arg-Gly-Asp (RGD) 
sequence which facilitates cell attachment signaling by binding to cell surface integrins (Fisher et al. 
2001). More recently, work by Peter Rowe and colleagues, primarily focused upon MEPE, has 
identified a new functional domain termed the ASARM peptide (acidic serine- and aspirate-rich 
motif) which is highly conserved between the SIBLING family members (Rowe et al. 2000; Rowe et 
al. 2004). This peptide is proving critical in the functional activity of the SIBLING proteins. The 
SIBLING proteins and their ASRAM motifs have individually been the subject of several excellent 
reviews, as are detailed later. In this review we focus upon the role in which each of the SIBLING 
proteins have on skeletal matrix mineralisation and bone remodelling, as well as their clinical 
relevance in disorders of bone mineralisation.        
Matrix mineralisation and bone remodelling   
Endochondral ossification is a carefully orchestrated process attributed to the formation and postnatal 
linear growth of the long bones. It involves the replacement of a cartilage scaffold by mineralised 
bone. Integral to this process is the epiphyseal growth plate, a highly specialied cartilaginous structure 
derived from a mesenchyme precursor that is located between the head and the shaft of the bone. The 
growth plate consists of chondrocytes arranged in columns that parallel the axis of the bone 
surrounded by their extracellular matrix (ECM) (Mackie et al. 2008; Ballock & O'Keefe 2003) which 
is rich in collagens, proteoglycans and numerous other NCPs (Gentili & Cancedda 2009; Heinegard 
2009). The chondrocytes of the growth plate sit in distinct cellular zones of maturation as are clearly 
visible (Fig. 1), and proceed through various stages of differentiation whilst maintaining their spatially 
fixed locations (Hunziker et al. 1987). It is the terminally differentiated hypertrophic chondrocyte that 
mineralizes its surrounding ECM, localized to the longitudinal septa of the growth plate (Castagnola 
et al. 1988).  
Chondrocyte, as well as osteoblast, mineralization of the ECM is widely accepted to involve 
membrane-limited matrix vesicles (MVs) within which calcium (Ca2+) and inorganic phosphate (Pi) 
accumulate to initiate the bi-phasic process of mineralization (Anderson 2003). When sufficient 
concentrations of both exist, calcium phosphate begins to precipitate to form HA crystals. This initial 
stage of mineralization is followed by the penetration of the MV trilaminar membrane by the HA 
crystals and the modulation of ECM composition, promoting the propagation of hydroxyapatite (HA) 
outside of the MVs (Anderson 2003; Anderson 1995; Wu et al. 2002; Golub 2011). Mineralization of 
the ECM is a tightly regulated process such that concentrations of Ca2+ and Pi are permissive for 
effective mineralization, and that the levels of mineralization inhibitors such as inorganic 
pyrophosphate (PPi) are balanced. Extracellular PPi is a well recognised and potent inhibitor of 
mineralization (Meyer 1984) that is regulated by alkaline phosphatase (ALP). In bone, ALP is a 
ectoenzyme enzyme located on the cell membrane’s outer surface of osteoblasts and chondrocytes, as 
well as on the membrane of their MVs (Anderson 1995). Classically, ALP was thought to generate the 
Pi required for HA formation, however it has since been shown to also hydrolyse PPi thus achieving a 
ratio of Pi/PPi permissive for HA crystal formation and growth (Fig. 2) (Hessle et al. 2002; Anderson 
2003; Moss et al. 1967; Majeska & Wuthier 1975). PPi inhibits the enzymatic activity of ALP 
(Addison et al. 2007) offering a feedback loop by which mineralization is mediated. Other regulators 
of ECM biomineralization include nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) and the 
Ankylosis protein (ANK) which work in synergy to increase extracellular PPi levels (Fig. 2). Whilst 
NPP1 ectoplasmically generates PPi from nucleoside triphosphates , ANK mediates its intracellular to 
extracellular channelling (Ho et al. 2000; Hakim et al. 1984; Terkeltaub et al. 1994). Analysis of mice 
deficient in ALP function (Akp2-/-) which are normally mineralized at birth has lead to the 
identification of other phosphatases such as PHOSPHO1. Since its discovery and characterisation, 
PHOSPHO1 has been proposed to play a crucial role in the accumulation of Pi within the MV and 
bone mineralisation (Stewart et al. 2006; Roberts et al. 2008; Roberts et al. 2007; MacRae et al. 2010; 
Houston et al. 2002). PHOSPHO1 has a non-redundant functional role during bone 
mineralisation and the ablation of both PHOSPHO1 and ALP results in the complete lack of 
bone mineralisation throughout the whole skeleton (Yadav et al. 2011) 
Mineralization of the ECM not only facilitates the deposition of HA, but also enables vascular 
invasion; a significant phase in the development of the skeleton. Vascular invasion allows the 
infiltration of osteoclasts and differentiating osteoblasts which absorb the cartilaginous mineralized 
matrix and replace it with trabecular bone respectively. This synergistic process of resorption and 
formation continues throughout life, replacing approximately 10% of the adult skeleton every year 
(Frost 1990). Despite this, the net effect of osteoblasts and osteoclasts on bone mass is zero to ensure 
disorders such as osteoporosis or osteopetrosis do not occur. During bone resorption, osteoclasts 
adhere to the bone surface forming a tight connection and allowing efficient resorption through the 
release of acid and proteinases. Like bone formation, this is under tight control by a variety of 
autocrine, paracrine and endocrine factors, and is thought to be primarily regulated by the terminally 
differentiated osteoblast, the osteocyte (Henriksen et al. 2009; Hill 1998; Manolagas 2000).   
The SIBLING family of proteins 
(1) MEPE 
Matrix extracellular phosphoglycoprotein (MEPE) was originally identified as a substrate for PHEX 
(Phosphate regulating endopeptidase homolog, X-linked), a cell membrane associated glycoprotein. In 
bone, MEPE is primarily expressed by osteocytes, but Mepe mRNA expression has also been 
observed by chondrocytes and osteoblasts (Nampei et al. 2004)(REF). Mepe mRNA is detected as 
early as 2-days postpartum in the mouse skeleton (Lu et al. 2004). Several regulators of Mepe mRNA 
expression are documented in the literature. The addition of fibroblast growth factor 2 (FGF2) to 
osteoblasts down regulates Mepe mRNA levels in a dose dependent manner. The mechanism of action 
is part through the mitogen-activated protein kinase (MAPK) pathway (Zhang et al. 2004). 
Furthermore, osteoblasts stimulated with bone morphogenetic protein 2 (BMP2) also display a 
decreased Mepe mRNA expression level (Siggelkow et al. 2004).  
The first evidence for a direct role of MEPE in bone mineralization came from the increased mRNA 
expression levels of Mepe seen during osteoblast matrix mineralization (Argiro et al. 2001; Petersen 
et al. 2000). The development of a MEPE null mouse further fuelled the proposed role for MEPE in 
mineralization. This mouse model had increased bone mass, with associated increased numbers and 
thickness of trabeculae. The mineral apposition rate (MAR) was dramatically increased as was the 
activity of MEPE null osteoblasts in culture (Gowen et al. 2003). Conversely, the overexpression of 
MEPE in mice, under the control of the coll1a1 promotor, leads to a growth and mineralization defect, 
due to a decrease in bone remodelling. The MEPE transgenic mice displayed wider epiphyseal growth 
plates, and expanded primary spongiosa and a significant decrease in the MAR (David et al. 2009).  
Like the other SIBLING proteins, the activity of MEPE is dependent upon its state of cleavage and its 
phosphorylation. Recent work has identified the 2.2kDa ASARM peptide of MEPE as the central 
provider for the mineralization activity of MEPE. This ASARM peptide is highly conserved across 
the SIBLING proteins and in MEPE, is located immediately downstream of a cathepsin B cleavage 
site (Rowe et al. 2000). The administration of the MEPE-ASARM peptide in vitro and in vivo can 
inhibit the uptake of Pi. This is likely through a decreased expression of the NPT2a renal phosphate 
transporter, or through the promotion of FGF23 expression, a potent inhibitor of Pi reabsorption 
(David et al. 2010; Dobbie et al. 2008; Shirley et al. 2010; Marks et al. 2008; Liu et al. 2007b; Martin 
et al. 2008). It has however been suggested that MEPE may have a direct effect on matrix 
mineralization outwith the supply and demand of Pi. The ASARM peptide of MEPE inhibits 
mineralization in osteoblasts by directly binding to HA crystals (Martin et al. 2008; Addison et al. 
2008). This inhibitory effect has also been shown in growth plate chondrocytes (REF). Integral to this 
inhibitory effect is the post translational phosphorylation of the ASARM peptide at three serine 
residues. In osteoblasts it appears that without this phosphorylation, the ASARM peptide has no effect 
on mineralization (Martin et al. 2008; Addison et al. 2008) however in chondrocytes, it appears the 
non-phosphorylated ASARM peptide can promote matrix mineralization (REF). This is not the only 
evidence for a role for MEPE in the promotion of mineralization. Recently it has been shown that a 
truncated form of MEPE which has the ASARM peptide removed, can promote bone mineralization 
in culture and in mice (Sprowson et al. 2008). Furthermore, a mid-terminal fragment of MEPE 
(termed ‘AC100’) has been shown to enhance cell binding, through the stimulation of focal adhesion 
kinase and extracellular signal-regulated kinases (ERK) (Hayashibara et al. 2004). Taken together, 
these results highlight the importance of post-translational processing in determining the functional 
role of MEPE.  
The interaction between MEPE and PHEX is well documented in the literature. PHEX plays a central 
role in the protection of MEPE from proteolytic cleavage by cathepsin B; it can bind to MEPE and 
prevent the release of the ASARM peptide (Guo et al. 2002). The Hyp mouse, a spontaneous Phex 
knockout model, has an increased expression of cathepsin D, an upstream activator of cathepsin B 
(Rowe et al. 2006). This therefore suggests that PHEX can alter the activation of cathepsin B, and 
therefore the cleavage of MEPE to the ASARM peptide. Furthermore, PHEX can bind to free 
ASARM peptides therefore neutralizing their activity by sequestration and hydrolysis (Addison et al. 
2008; Martin et al. 2008; Liu et al. 2007a).  
MEPE transgenic mice display a decrease in ALP enzyme activity in both the growth plate and the 
primary spongiosa (David et al. 2009). In vivo, the addition of the phosphorylated ASARM peptide 
also reduced the number of ALP-positive cells in an osteoblast cell culture model (Martin et al. 2008). 
However, this remains controversial as normal ALP activity has been reported in osteoblasts  treated 
with phosphorylated ASARM peptide (Addison et al. 2008). No difference was also observed in the 
metatarsal organ culture used to examine the effects of the ASARM peptide on chondrocyte 
mineralization. Intriguingly, this metatarsal model also showed that in chondrocytes, the 
phosphorylated ASARM peptide directly inhibits angiogenesis through an inhibition of VEGF and 
other markers associated with vascularisation (REF). Contradictory to this, in the MEPE 
overexpressing mouse vascularisation was increased, as was VEGF expression (David et al. 2009). 
Consonant with angiogenesis is the infiltration of osteoclasts for bone resorption. Interestingly, in 
mice administered with recombinant MEPE or transgenic for MEPE  had  a significant decrease in the 
numbers and activity of osteoclasts (David et al. 2009; Hayashibara et al. 2007).  
(2) OPN 
Osteoponin (OPN), also known as secreted phosphoprotein I (SPI), is a 34kDa protein, originally 
identified as the bridge between the cells and HA in the ECM of bone (Sodek et al. 2000). The protein 
and gene structure, as well as the localisation, of OPN are well described in several excellent reviews 
(Fisher et al. 2001; Sodek et al. 2000; Denhardt & Guo 1993). In bone, OPN is produced by 
osteoblasts and osteocytes (Zohar et al. 1997; Sodek et al. 1995), as well as osteoclasts (Dodds et al. 
1995). It has also been localized to hypertrophic cartilage of the growth plate (Landis et al. 2003). 
This broad expression of OPN reflects its vast hormonal, cytokine and growth factor regulation.  
Several studies have documented the inhibitory role of OPN in HA formation and growth (Hunter et 
al. 1994; Boskey et al. 1993). It has also been shown to inhibit mineralization in vascular smooth 
muscle cells (Jono et al. 2000; Wada et al. 1999). This inhibitory role for OPN is confirmed further by 
analysis of the OPN knockout mouse which has increased mineral content and size, as shown by FT-
IR analysis in two different lines of Opn-/- mice at two different ages (Boskey et al. 2002). More 
specifically, it has recently been shown that the ASARM peptide of OPN inhibits ECM matrix 
mineralization by binding to HA crystals (Addison et al. 2010). This study by Addison et al also 
showed that, like MEPE,  the ability of the OPN-ASARM to inhibit mineralization is dependent upon 
its phosphorylation at specific serine residues (Addison et al. 2010). However, the phosphorylation of 
other serine residues outwith the ASARM motif can also inhibit HA formation (Pampena et al. 2004). 
This therefore emphasises the essentiality of phosphorylation in the functional capability of OPN to 
inhibit ECM mineralisation. This is further confirmed when examining the interaction between OPN, 
ALP and PPi. Several studies have shown that ALP dephosphorylates OPN, thus preventing much of 
its inhibitory activity on HA formation and growth (Boskey et al. 1993; Jono et al. 2000; Hunter et al. 
1994). Furthermore, PPi directly upregulates OPN mRNA expression in osteoblasts, therefore the 
hydrolysis of PPi by ALP will have a significant effect on the expression levels of OPN (Addison et 
al. 2007). This is in concordance with the Enpp1 deficient mouse in which the PPi deficiency brings 
about a deficiency in OPN (Johnson et al. 2003). This is also seen in the Akp2 deficient mouse, and is 
further confirmed by the Akp2-/-/Opn-/- mouse in which the hypomineralization seen in the Akp2-/- 
mouse alone is partially rescued (Harmey et al. 2006).  
Although previous studies have implicated a phosphate dependent mechanism (Beck, Jr. et al. 2000; 
Beck, Jr. & Knecht 2003), work by Addison and colleagues has implicated the MAPK signaling 
pathways as responsible for the regulation of OPN by PPi. Analysis of the Opn-/- mouse has also 
indicated a role for OPN in the function and activity of osteoclasts. An increase in osteoclast 
production by spleen cells from mice lacking OPN was observed (Rittling et al. 1998). This could be 
a compensatory mechanisms for the disabled motility and resorption activity in osteoclasts deficient in 
OPN (Chellaiah et al. 2003). Further studies have attempted to elucidate the precise role of OPN in 
bone resorption and have implicated CD44,  a major cell-surface receptor for hyaluronate (Aruffo et 
al. 1990) and a receptor for OPN (Suzuki et al. 2002; Chellaiah et al. 2003). 
 
(3) BSP  
Bone sialoprotein (BSP) is a 70-80kDa protein for which its gene and protein structure have been 
extensively  reviewed (Ganss et al. 1999). The localisation of BSP is unique to the SIBLING family 
of proteins as it is exclusively located to mineralized tissues such as bone, dentin and mineralizing 
cartilage (Chen et al. 1991; Bianco et al. 1991). In bone, it is expressed in abundance by osteoblasts, 
as well as by osteoclasts, osteocytes and chondrocytes (Gordon et al. 2007; Fisher & Fedarko 2003; 
Gordon et al. 2007).  
During embryogenesis, BSP is first expressed at the onset of bone formation thus suggesting BSP to 
be a strong candidate for a role in HA nucleation (Chen et al. 1992). This certainly seems convincing 
as numerous studies have documented BSP to be involved in the initial formation of HA (Fisher et al. 
2001; Harris et al. 2000; Tye et al. 2003; Wang et al. 2006). Indeed it has been shown that as little as 
9nM BSP is required to nucleate HA and recently the overexpression of BSP in osteoblasts has been 
shown to enhance mineralization (Gordon et al. 2007; Hunter et al. 1996). Similarly, osteoblast 
cultures grown in the presence of an anti-BSP antibody exhibit reduced mineralization (Cooper et al. 
1998; Mizuno et al. 2000). This nucleation potency is increased upon BSP binding to ????? 
suggesting a co-operative relationship between the two (Baht et al. 2008).  
This nucleation has been reported to involve the membrane bound enzyme, ALP, where high. levels 
of ALP activity can promote the initiation of mineral deposition in the presence of BSP (Wang et al. 
2006). This is further confirmed in BSP overexpressing cell cultures which have a higher ALP 
activity (Valverde et al. 2008). It is likely that, like the other SIBLING proteins, the function of BSP 
is highly dependent upon its PTM (Stubbs, III et al. 1997). In bone remodelling, BSP is crucial for the 
maintenance of osteoblast and osteoclast homeostasisc coupling. BSP increases osteoclastogenesis 
and therefore bone resorption (Valverde et al. 2005; Ross et al. 1993; Raynal et al. 1996). 
Furthermore, BSP expression in bone diseases characterised by excessive bone resorption, e.g. Pagets 
disease, is abnormally high (Valverde et al. 2008). This has been further examined in BSP transgenic 
mice in which an uncoupling of bone formation and resorption resulted in an osteopenia-like 
phenotype (Valverde et al. 2008). 
(4) DSPP 
The role of dentin sialophosphoprotein (DSPP) in biomineralization has recently been reviewed 
(Prasad et al. 2010). Although originally thought to be exclusively expressed by dentin, DSPP is also 
expressed in bone, cementum and in non-mineralizing tissues including the lung and kidney (Verdelis 
et al. 2008; Alvares et al. 2006; Ogbureke & Fisher 2007; Qin et al. 2002; Baba et al. 2004).  
DSPP is proteolytically processed to two fragments, dentin phosphoprotein (DPP) and dentin 
sialoprotein (DSP); both of which have important functions in mineralization. Interestingly, a third 
fragment called dentin glycoprotein (DGP) has been identified as being cleaved from the C-terminal 
end of DSP by MMP-2 and MMP-20 (Yamakoshi et al. 2005). It has been suggested that the 
proteolytic processing of DSPP to DPP, DSP and DGP is the activating stage in the mechanism of 
DSPP function (Prasad et al. 2010; Qin et al. 2004; Zhang et al. 2001). Analysis of the DSPP 
knockout mouse reveals defects in both dentin mineralization (Sreenath et al. 2003), as well as bone 
mineralization (Verdelis et al. 2008). In humans, a mutation in the DSPP gene results in 
dentinogenesis imperfecta characterized by dentin hypomineralization and significant tooth decay 
(Kim et al. 2005). 
Of particular interest are the variations in the mineralization properties observed at different ages in 
the Dspp-/- mouse. This suggests that DSPP has roles in not only the initial mineralization of bone, but 
also in the remodelling of the skeleton. Various studies have shown DPP to be important in the 
formation and growth of HA as it has a strong affinity to Ca2+ when bound to collagen fibrils (Boskey 
et al. 1990; Saito et al. 1997; He et al. 2005). The phosphorylation of DPP is believed to be crucial to 
its function since removal of the phosphate groups results in a loss of its role in HA promotion (Saito 
et al. 1997). On the other hand, although DSP has been shown to be involved in the initiation of 
mineralization, it appears not to have a functional role in the maturation of the tissue (Suzuki et al. 
2009). The mechanism by which DSPP regulates HA formation is thought to involve the canonical 
BMP2 signaling pathway as BMP2 has been shown to increase DSPP mRNA expression via BMP-R 
Smads, Runx2 and DIx5 (Cho et al. 2010; Iohara et al. 2004; Chen et al. 2008).  
(5) DMP1 
Dentin matrix protein 1 (DMP1) was first cloned from dentin (George et al. 1993) and has since been 
identified in dentin, bone, and cementum (MacDougall et al. 1998), as well as other non-mineralized 
tissues (Sun et al. 2011). In bone, DMP1 is primarily expressed by osteocytes (Toyosawa et al. 2001) 
but also by osteoblasts (Feng et al. 2003) and hypertrophic chondrocytes (Fen et al. 2002). The first 
evidence for a role for DMP1 in biomineralization was its promotion of ECM mineralization in 
MC3T3 cells overexpressing DMP1 (Narayanan et al. 2001). The generation of a Dmp1-null mouse 
has further fuelled the potential role for DMP1 in bone mineralization. The mineral-matrix properties 
of the knockout mice were significantly lower when compared to their control counterparts (Ling et 
al. 2005). Furthermore, the DMP1 deficient mice displayed a severe defect in cartilage formation with 
a highly widened growth plate suggesting an impairment of mineralisation at the chondro-osseous 
junction. Indeed, this cartilage defect results in a phenotype resembling dwarfism with 
chondrodysplasia (Ye et al. 2005) and highlights the role of DMP1 in chondrocyte matrix 
mineralization. It has since been shown that the distorted growth plates seen in the DMP1 null mouse 
are in fact due to disorganisation as opposed to enlargement of what??? (Sun et al. 2010). 
Furthermore, this disorganisation can be recovered by crossing the DMP1 null mouse with transgenic 
mice expressing a mutant form of DMP1, which blocks the processing of mouse DMP1 in vivo (Sun 
et al. 2011). Like other SIBLING proteins, the proteolytically processing of DMP1 appears essential 
to its function and localization. In bone and dentin, DMP1 is processed to two fragments; one 37kDa 
fragment originating from the NH2-terminal, and one 57kDa fragment originating from the COOH-
terminal (Qin et al. 2003). In DMP1, it is the COOH-terminal fragment that contains the ASARM 
motif (Martin et al. 2008). The full length DMP1 is expressed at much lower levels (Huang et al. 
2008)  than its fragments which themselves have different localization patterns in bone (Maciejewska 
et al. 2008). In the growth plate, whilst the NH2-terminal fragment is localized to the resting, 
proliferation and pre-hypertrophic zones, the COOH-terminal fragment is found in the calcification 
front and ossification zone (Maciejewska et al. 2008). The localization of the COOH-terminal 
fragment is consistent with areas that are targets for the vascular invasion of the cartilage, a significant 
phase in matrix mineralization. DMP1 has been postulated to play a role in angiogenesis as treatment 
with DMP1 induced vascular endothelial cadherin (VE-cadherin), and inhibited the VEGFR-2 
activity, therefore suggesting DMP1 to be an inhibitor of VEGF-induced angiogenesis (Pirotte et al. 
2011). The direct role of DMP1 on HA formation is highly dependent upon its processing, and it’s 
PTM. When phosphorylated, full length DMP1 has been shown to inhibit the formation and growth of 
HA (Tartaix et al. 2004), however, its dephosphorylated form and its two fragments are well 
established nucleators of HA formation (Tartaix et al. 2004; He et al. 2003; Gericke et al. 2010). Thus 
native DMP1 inhibits mineralization unless it becomes cleaved or dephosphorylated, in which case it 
initiates mineralization (Tartaix et al. 2004). The signaling pathways involved in DMP1 function have 
recently been investigated in osteoblasts. Wu et al., 2011 showed DMP1, through the activation of the 
αvβ3 integrin, to activate the downstream effectors of the MAPK pathway, ERK and JNK (Wu et al. 
2011). Concomitant to this is the stimulation of phosphorylated JNK translocation coupled with an 
up-regulation of phosphorylated c-jun activation (Wu et al. 2011). Furthermore, it has been shown 
that the internalization of DMP1 not only results in a release of stored Ca2+, but also activates p38 
MAP kinase (Eapen et al. 2011). DMP1 null mice have distinct abnormalities in the morphology and 
maturation of their osteocytes (Feng et al. 2006). The two DMP1 fragments also display differing 
localization patterns in osteocytes (Maciejewska et al. 2009), suggesting that osteocytes may play a 
critical role in ECM mineralization that involves DMP1. This is further supported by the stimulation 
of DMP1 expression in response to mechanical loading (Gluhak-Heinrich et al. 2007). Furthermore, 
the deletion of DMP1 leads to a dramatic increase in Fgf23 mRNA expression in the osteocytes, likely 
due to the defects seen in osteoblast-osteocyte transition (Feng et al. 2006; Qin et al. 2007). FGF23, a 
hormone produced by osteoblasts and osteocytes, has allowed the definition of bone as an endocrine 
organ as it targets the kidney to regulate Pi homeostasis. This therefore suggests that DMP1 can 
control Pi levels, as is in concurrence with the hypophosphatemia observed in the DMP1 null mouse 
(Feng et al. 2006; Ye et al. 2005).  
SIBLING ASARM peptides in mineralization diseases  
Accumulating evidence has implicated the members of the SIBLING family of proteins in bone and 
mineralization diseases. Their varying involvements in the process of matrix mineralization make 
them potentially attractive candidates for therapeutic targets and therapies.  
X-linked hypophosphatemic rickets (XLH) is the most common form of inherited rickets, 
characterised by defective bone and tooth mineralization, growth retardation, and defective renal re-
absorption of Pi (Carpenter et al. 2011). Mutations in PHEX,  have been associated with XLH in 
humans, and have led to the development of the Hyp mouse (Holm et al. 1997). Hypophosphatemia 
alone is insufficient to explain the bone defect seen in the Hyp mouse as correction of the 
hypophosphatemia failed to correct the mineralization defect observed (Ecarot et al. 1992; Rowe et al. 
2006). Furthermore, when osteoblast cells from the Hyp mouse are grown in culture, they have a 
defective ECM production and thus reduced mineralization (Xiao et al. 1998). This therefore suggests 
that PHEX has multiple substrates which are involved in regulating mineralization directly. MEPE 
was first identified as a potential substrate for PHEX however in vitro studies have failed to 
demonstrate PHEX-dependent hydrolysis of MEPE (Guo et al. 2002). It has also been suggested that 
PHEX is likely responsible for the cleavage of DMP1 and DSPP, as it has a strong preference for 
cleaving bonds at the N-terminal of aspartyl residues found in these two SIBLING proteins (Qin et al. 
2004). However analysis of the Hyp mouse indicated no differences in DMP1 and DSPP mRNA 
expression in comparison to their wild-type controls, suggesting that DMP1 and DSPP are in fact 
properly processed in the PHEX-deficient mouse (Zhang et al. 2010). In addition to this, there is an 
accumulation of SIBLING ASARM peptides in the Hyp mouse and patients with XLH (Bresler et al. 
2004; Martin et al. 2008; Boukpessi et al. 2010) thus challenging the hypothesis that the SIBLING 
proteins are substrates for PHEX. Instead it appears that it is the ASARM peptide which PHEX 
digests (Addison et al. 200, 2010). This therefore provides compelling evidence for the ASARM 
hypothesis, as proposed by Peter Rowe, which describes the role of the SIBLING ASARM peptides, 
PHEX, and FGF23 in bone renal phosphate homeostasis, and therefore mineralization (Fig. 2) (Rowe 
2004; David et al. 2010). This hypothesis can be used to explain numerous disorders of mineralization 
including tumor-induced osteomalacia, autosomal-dominant hypophosphatemic rickets, and XLH. 
The potential for a therapeutic treatment is therefore high however further elucidation of the exact 
mechanisms involved is required.          
Conclusions 
The aim of this review is to present an overview of the role that each member of the SIBLING family 
of proteins has in matrix mineralization. The SIBLING proteins are principally found in bone and 
dentin, and are secreted into the ECM during its formation and subsequent mineralization. It is 
apparent that the functional role of the SIBLING proteins is highly dependent upon their state of 
cleavage and their post translational modification (Table 1). Furthermore, the identification of the 
ASARM motif which is present across the SIBLING proteins is proving critical in the functional 
activity of the SIBLING proteins. Much remains to be learnt regarding the in vivo role of the 
SIBLING protein and the ASARM peptide in bone disease. Future investigations should focus upon 
determining the interactions between the SIBLING proteins and the potential therapeutic use that they 
may have.  
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